2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-105257
    Pranazepide 150408-73-4 99.81%
    Pranazepide (FR120480) is a selective cholecystokinin-1 receptor (CCK1-R) antagonist with an IC50 of 0.67 nM against CCK1-R. Pranazepide is applicable for the research of pancreatic diseases.
    Pranazepide
  • HY-105791
    Sulazepam 2898-13-7 99.56%
    Sulazepam, a benzodiazepine, is a selective ovarian cancer G protein-coupled receptor (OGR1) agonist. Sulazepam has anticonvulsive action and has the potential for airway hyperresponsiveness (AHR) research.
    Sulazepam
  • HY-105808
    Furobufen 38873-55-1 99.74%
    Furobufen, an anti-inflammatory agent, produces antiarthritic, antipyretic effects. Furobufen has an analgesic effect in inflamed tissue.
    Furobufen
  • HY-106003
    GSK356278 720704-34-7 99.82%
    GSK356278 is a potent, selective, orally bioavailable and brain-penetrant inhibitor of phosphodiesterase 4 (PDE4), with pIC50s of 8.6, 8.8, and 8.7 for human PDE4A, PDE4B, and PDE4D, respectively. GSK356278 has anti-inflammatory activity, and exhibits anxiolytic and cognition-enhancing effects.
    GSK356278
  • HY-106199
    Adenosine A1 receptor activator T62 40312-34-3 ≥98.0%
    Adenosine A1 receptor activator T62 is an allosteric enhancer of adenosine A1 receptor. Adenosine A1 receptor activator T62 produces antinociception in animal models of acute pain and also reduces hypersensitivity in models of inflammatory and nerve-injury pain.
    Adenosine A1 receptor activator T62
  • HY-106579
    Tiaprofenic acid 33005-95-7 ≥98.0%
    Tiaprofenic acid is an orally active nonsteroidal anti-inflammatory agent (NSAID) with anti-inflammatory and analgesic potency. Tiaprofenic acid inhibits prostaglandin synthesis by suppressing cyclo-oxygenase (COX). Tiaprofenic acid can be used in the treatment of rheumatic diseases.
    Tiaprofenic acid
  • HY-106583
    Piroxicam cinnamate 87234-24-0 99.19%
    Piroxicam cinnamate (Cinnoxicam) is a cyclooxygenase (COX) inhibitor, with anti-inflammatory activity. Piroxicam cinnamate is stable under gastric conditions, can be used for inflammatory-degenerative osteoarticular diseases, rheumatic disorders, and varicocele (VC) associated oligoasthenospermia research.
    Piroxicam cinnamate
  • HY-106647
    Abacavir hydroxyacetate 1446418-48-9 99.61%
    Abacavir hydroxyacetate is an orally active inhibitor of IL-20 and PRINS. Abacavir hydroxyacetate reduces proliferation rate of skin in psoriasis as an immune modulator. Abacavir hydroxyacetate can be used for the research of inflammatory skin problems.
    Abacavir hydroxyacetate
  • HY-106690
    Centhaquin 57961-90-7 99.93%
    Centhaquine (Centhaquin; PMZ-2010) is a novel agent has the potential for treatment of haemorrhagic shock. Centhaquine (Centhaquin; PMZ-2010) can augment cardiac output, reduce systemic vascular resistance in haemorrhagic models.
    Centhaquin
  • HY-107101
    (5R)-5-Hydroxytriptolide 583028-68-6 99.67%
    (5R)-5-Hydroxytriptolide is an extracted compound from Tripterygium, and shows lower cell cytotoxicity and higher immunosuppressive activity. (5R)-5-Hydroxytriptolide can be used for study of rheumatoid arthritis.
    (5R)-5-Hydroxytriptolide
  • HY-107260
    Lucidenic acid D 98665-16-8 99.78%
    Lucidenic acid D is a highly oxidized triterpenoid with anti-inflammatory and antiviral activities. Lucidenic acid D attenuates lipopolysaccharide-induced release of proinflammatory cytokines and nitric oxide, reduces the expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2), and inhibits skin inflammation. Lucidenic acid D suppresses 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced expression of Epstein-Barr virus (EBV) early antigen and maintains the viability of Raji cells. Lucidenic acid D can be used in studies of cancer chemoprevention.
    Lucidenic acid D
  • HY-107600
    IQ-3 312538-03-7 99.61%
    IQ-3 is a specific inhibitor of the c-Jun N-terminal kinase (JNK) family, with preference for JNK3. IQ-3 exhibits Kd values of 0.24 μM, 0.29 μM and 0.066 μM for JNK1, JNK2 and JNK3, respectively.
    IQ-3
  • HY-107634
    CP-20961 35607-20-6 98.34%
    CP-20961 is an interferon inducer. CP-20961 is a potent synthetic non-immunogenic adjuvant that induces arthritis.
    CP-20961
  • HY-107682
    TQS 353483-92-8 99.84%
    TQS is a α7 nicotinic acetylcholine receptor (nAChR) positive allosteric modulator. TQS can be used for the research of neuroinflammatory pain.
    TQS
  • HY-107831
    5-Acetylsalicylic acid 13110-96-8 99.84%
    5-Acetylsalicylic acid is the derivate of Aspirin (HY-14654), with anti-inflammatory property. 5-Acetylsalicylic acid is the active metabolite of Sulfasalazine (HY-14655) and its production is regulated by beneficial bacteria in the gut but is confined to the intestinal tract. 5-Acetylsalicylic acid exhibits a mild cytotoxicity effect on B16F10 cells. 5-Acetylsalicylic acid can be used for the study of inflammatory bowel disease (IBD) such as ulcerative colitis (UC).
    5-Acetylsalicylic acid
  • HY-108458
    SB 452533 459429-39-1 99.11%
    SB 452533 is a potent and selective TRPV1 antagonist with the pKb of 7.8.
    SB 452533
  • HY-108483
    RP 67580 135911-02-3 99.05%
    RP 67580 is a non-peptide antagonist of substance P (SP), competitively inhibits the binding of [3H]SP to neurokinin receptor 1 (NK1 receptor) in rat brain membranes with a Ki value of 4.16 nM. RP 67580 is a specific antagonist of NK1 receptors and can be used in the research of pain and neurogenic inflammation.
    RP 67580
  • HY-108548
    Rp-8-Br-PET-cGMPS sodium 185246-32-6 99.42%
    Rp-8-Br-PET-cGMPS sodium (Rp-8-Bromo-PET-cGMPS) is an analog of cyclic GMP (cGMP). It is a cell permeable, competitive, and reversible inhibitor of cGMP-dependent protein kinases (cGKs) that blocks activation of cGKI and cGKII by cGMP (Kis=35 and 30 nM). It less potently inhibits protein kinase A (Ki=11 μM) and cGMP-induced activation of cyclic nucleotide-gated channels (IC50=25 μM). In the absence of cGMP stimulation, Rp-8-bromo-PET-cGMPS can act as a partial agonist of cGKI (Ki=1 μM). Rp-8-bromo-PET-cGMPS is resistant to hydrolysis by phosphodiesterase 11.
    Rp-8-Br-PET-cGMPS sodium
  • HY-108647
    EO 1428 321351-00-2 99.65%
    EO 1428 is a highly specific inhibitor of p38 of the aminobenzophenone class. EO 1428 (1 μM ) markedly attenuates LPS-induced tumor necrosis factor α-converting enzyme (TACE) activity up-regulation.
    EO 1428
  • HY-110047
    CB65 913534-05-1 98%
    CB65 is a potent and high affinity CB2 selective agonist with a Ki value of 3.3 nM. CB65 exhibits a Ki of >1000 nM for CB1 receptor.
    CB65
Cat. No. Product Name / Synonyms Application Reactivity